We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cellular Energy Regulation Key to Fighting Cancer

By Biotechdaily staff writers
Posted on 01 Sep 2005
In an attempt to combat disease by modifying energy regulation of cells, a collaborative study has shown that cells lacking a tumor-suppressing kinase called LKB1 can still maintain healthy energy levels when they become stressed. More...


This energy management is needed for keeping cells from dying off too soon. The study's findings could lead to new advances for fighting cancer, in addition to potential treatments for type 2 diabetes and obesity.

The study, published in the August 12, 2005, issue of the Journal of Biological Chemistry, was led by Dr. Lee Witters, from Dartmouth University Medical School (DMS, Hanover, NH, USA). Kinases include a large family of enzyme proteins that play major roles in the functioning of most cells in living organisms. Dr. Witters has focused much of his research on the AMP-activated kinase (AMPK), which is responsible for regulating energy within cellular pathways.

"A cell's energy level is critical to its survival,” explained Dr. Witters, who compared a low-energy cell to a car with an empty tank. "In a previous study, we found that the cellular ‘gas gauge,' AMPK, can turn around and alter any deficits in the cell if it is turned on by the kinase LKB1. In this study, we wanted to see if AMPK could also be turned on by something besides LKB1.”

"We decided to work with cervical and lung cancer cells because LKB1 is absent from the cellular pathway,” said Rebecca Hurley, lead author of the study and a graduate student in the molecular and cellular biology program at Dartmouth. Working closely with scientists at St. Vincent's Institute (Victoria, Australia) and Duke University (Durham, NC, USA), the DMS team concluded that two kinases in these cancer cells, CaMKKa and CaMKKß, are able to regulate AMPK independent of LBK1.

"With the addition of these two kinases, we think we have all nearly the players responsible for energy regulation within the cell, which should offer new opportunities in cancer treatment,” added Ms. Hurley. "If we can stifle a cancer cell's ability to adapt to an energy deficit, it might lose its growth advantage.”

"You need to know how all these proteins interact before you can make truly significant advances,” noted Dr. Witters "It's like poker; not only do you need to know what each card signifies individually, but you must have an understanding of how they play off each other in order to win.”

In addition to cancer-fighting potential of AMPK regulation, the enzyme also reacts to alterations in glucose or insulin and mediates faulty energy metabolism, a characteristic of type 2 diabetes. "This indicates that AMPK is a very tempting target for the treatment of some forms of diabetes and even obesity,” stated Dr. Witters.

As these investigators continue to narrow in on the key role of kinases in the treatment of disease, they recognize that this study is becoming more complicated and multiple approaches are needed to find solutions. Dr. Witters believes that major breakthroughs in science can only be achieved through open collaboration, citing partnerships between faculty and students, and between other institutes in the scientific and medical communities.

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
Manual Pipetting Aid
Pipette Controllers macro
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.